Results 191 to 200 of about 396,333 (302)

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure‐Response Analyses

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow   +3 more
wiley   +1 more source

Functional characterization of the chaperone DnaK of Riemerella anatipestifer in antibiotic resistance and pathogenicity. [PDF]

open access: yesPoult Sci
Guo F   +16 more
europepmc   +1 more source

Examining the Financial Impact of Biodiversity‐Related Reputational Disasters

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This research investigates the reaction of financial markets to biodiversity‐related corporate events, utilising an EGARCH model to assess the implications on stock returns and volatility. Results reveal that markets significantly respond to these events, demonstrating heightened sensitivity and volatility that underscore the financial ...
Erdinc Akyildirim, Shaen Corbet
wiley   +1 more source

Identifying the True Catalyst: A Mn(II) Salt versus Mn(II) Complexes in Epoxidation with m‐Chloroperbenzoic Acid

open access: yesEuropean Journal of Organic Chemistry, Accepted Article.
The oxidant meta‐chloroperbenzoic acid (m‐CPBA) is used widely for the epoxidation of alkenes, yet its efficiency is often limited under ambient conditions. In this study we investigate the catalytic activity of a Mn(II) salt and mononuclear Mn(II) complexes, two of which are reported here for the first time, in the epoxidation of alkenes with m‐CPBA ...
Milica Savić   +7 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Assessing the feasibility of CRISPRa approaches to enhance protein-based biomaterial expression in bacterial systems for more efficient production. [PDF]

open access: yesMater Today Bio
Rodríguez-Alonso P   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy